Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
20%
Ph phase_1
1
20%
Ph phase_2
3
60%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Other(1)

Detailed Status

Completed2
Active, not recruiting1
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)

Trials by Status

active_not_recruiting120%
unknown120%
completed240%
not_yet_recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
not_yet_recruitingphase_1

HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer

NCT07587034
completedphase_2

A Study of TCD601 in de Novo Renal Transplant Recipients

NCT05669001
active_not_recruitingphase_2

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

NCT06019507
unknownphase_2

The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

NCT05471050
completedphase_3

Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer

NCT00544765

Clinical Trials (5)

Showing 5 of 5 trials
NCT07587034Phase 1

HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer

Not Yet Recruiting
NCT05669001Phase 2

A Study of TCD601 in de Novo Renal Transplant Recipients

Completed
NCT06019507Phase 2

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

Active Not Recruiting
NCT05471050Phase 2

The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Unknown
NCT00544765Phase 3

Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
5